- Home
- GNTA vs DRRX Comparison
GNTA vs DRRX Comparison
Compare GNTA & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- DRRX
- Stock Information
- Founded
- GNTA 2014
- DRRX 1998
- Country
- GNTA Italy
- DRRX United States
- Employees
- GNTA N/A
- DRRX N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- DRRX Health Care
- Exchange
- GNTA Nasdaq
- DRRX Nasdaq
- Market Cap
- GNTA 70.6M
- DRRX 59.0M
- IPO Year
- GNTA 2021
- DRRX 2000
- Fundamental
- Price
- GNTA $3.50
- DRRX $1.91
- Analyst Decision
- GNTA Strong Buy
- DRRX Hold
- Analyst Count
- GNTA 1
- DRRX 1
- Target Price
- GNTA $25.00
- DRRX N/A
- AVG Volume (30 Days)
- GNTA 4.2K
- DRRX 2.9M
- Earning Date
- GNTA 01-01-0001
- DRRX 08-12-2025
- Dividend Yield
- GNTA N/A
- DRRX N/A
- EPS Growth
- GNTA N/A
- DRRX N/A
- EPS
- GNTA N/A
- DRRX N/A
- Revenue
- GNTA N/A
- DRRX $1,657,000.00
- Revenue This Year
- GNTA N/A
- DRRX N/A
- Revenue Next Year
- GNTA N/A
- DRRX $673.00
- P/E Ratio
- GNTA N/A
- DRRX N/A
- Revenue Growth
- GNTA N/A
- DRRX N/A
- 52 Week Low
- GNTA $2.74
- DRRX $0.48
- 52 Week High
- GNTA $7.28
- DRRX $2.64
- Technical
- Relative Strength Index (RSI)
- GNTA 44.28
- DRRX 84.64
- Support Level
- GNTA $3.20
- DRRX $1.85
- Resistance Level
- GNTA $3.79
- DRRX $1.92
- Average True Range (ATR)
- GNTA 0.21
- DRRX 0.09
- MACD
- GNTA -0.04
- DRRX 0.01
- Stochastic Oscillator
- GNTA 49.40
- DRRX 10.98
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.